What is it about?
Introduction and importance: Non-vitamin K antagonist Oral Anti-Coagulants (NOACs) have emerged as an effective treatment for thromboembolic events with a reduced bleeding risk compared to traditional anti-vitamin K drugs. However, their role in managing antiphospholipid antibody syndrome remains a subject of debate.
Featured Image
Photo by Raimond Klavins on Unsplash
Why is it important?
Case presentation: We present the case of a 48-year-old man with a history of pulmonary embolism and a right cavitary thrombus, who was receiving treatment with a new-generation anticoagulant. Despite this treatment, he exhibited resistance, prompting further investigation that led to the diagnosis of antiphospholipid antibody syndrome.
Perspectives
Non-vitamin k antagonist Oral Anti-Coagulants (NOACs) represent a new class of anticoagulants that offer patients a simpler daily life with less complicated monitoring [1]. They have demonstrated their efficacy in the treatment and prevention of thromboembolic events while decreasing the risk of bleeding compared to anti-vitamin K (VKA) drugs [2].
Acquire Publications
Read the Original
This page is a summary of: Thrombotic Recurrence Under New Oral Anticoagulants Revealing Antiphospholipid Antibody Syndrome: Case Report, Journal of Case Reports and Medical History, January 2024, Acquire Publications LLC,
DOI: 10.54289/jcrmh2400103.
You can read the full text:
Contributors
The following have contributed to this page
